Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer

Proteomics - Clinical Applications

Volumn 2, Issue 9, 2008, Pages 1313-1326

  Durán, Ma Carmen ^a,b   Vega, Francisco ^a,d   Moreno Bueno, Gema ^c,e   Artiga, Ma Jesus ^c   Sanchez, Lydia ^c   Palacios, Jose ^c,f   Ridley, Anne ^a   Timms, John F ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

2 D DIGE; Breast cancer; ErbB2; Metastasis; Tissue microarrays

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTATHIONE TRANSFERASE P1; HEAT SHOCK PROTEIN 90; LAMININ; LIPOCORTIN 2; MASPIN; NUCLEOSIDE DIPHOSPHATE KINASE A; ONCOPROTEIN; PROTEIN AGR2; PROTEIN STARD10; PROTEIN TAGLN2; SMALL INTERFERING RNA; TRANSGELIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; GEL ELECTROPHORESIS; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KNOCKOUT GENE; MASS SPECTROMETRY; METASTASIS; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; TISSUE MICROARRAY; TUMOR GROWTH; VALIDATION PROCESS;

EID: 53549124106     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780020     Document Type: Article

References (47)

1. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J. et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
2. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J. et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17, 2639-2648.
3. Hynes, N. E., Lane, H. A., ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
4. Lin, N. U., Winer, E. P., New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004, 6, 204-210.
5. Suzuki, E., Toi, M., Improving the efficacy of trastuzumab in breast cancer. Cancer Sci. 2007, 98, 767-771.
6. Xia, W., Gerard, C. M., Liu, L., Baudson, N. M. et al., Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-over-expressing breast cancer cells. Oncogene 2005, 24, 6213-6221.
7. Oh, J. J., Grosshans, D. R., Wong, S. G., Slamon, D. J., Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res. 1999, 27, 4008-4017.
8. Alaoui-Jamali, M. A., Song, D. J., Benlimame, N., Yen, L. et al., Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer Res. 2003, 63, 3764-3774.
9. Mackay, A., Jones, C., Dexter, T., Silva, R. L. et al., cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 2003, 22, 2680-2688.
10. Wilson, K. S., Roberts, H., Leek, R., Harris, A. L., Geradts, J., Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am. J. Pathol. 2002, 161, 1171-1185.
11. White, S. L., Gharbi, S., Bertani, M. F., Chan, H. L. et al., Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. Br. J. Cancer 2004, 90, 173-181.
12. Gharbi, S., Gaffney, P., Yang, A., Zvelebil, M. J. et al., Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol. Cell. Proteomics 2002, 1, 91-98.
13. Unlu, M., Morgan, M. E., Minden, J. S., Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18, 2071-2077.
14. Palacios, J., Honrado, E., Osorio, A., Cazorla, A. et al., Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: Differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin. Cancer Res. 2003, 9, 3606-3614.
15. Weeks, M. E., Sinclair, J., Jacob, R. J., Saxton, M. J. et al., Stress-induced changes in the Schizosaccharomyces pombe proteome using two-dimensional difference gel electrophoresis, mass spectrometry and a novel integrated robotics platform. Proteomics 2005, 5, 1669-1685.
16. Chan, H. L., Gharbi, S., Gaffney, P. R., Cramer, R. et al., Proteomic analysis of redox- and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine- and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics 2005, 5, 2908-2926.
17. Cutillas, P. R., Chalkley, R. J., Hansen, K. C., Cramer, R. et al., The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by renal proximal tubule cells. Am. J. Physiol. Renal Physiol. 2004, 287, F353-F364.
18. Rae, J. M., Creighton, C. J., Meck, J. M., Haddad, B. R., Johnson, M. D., MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat. 2007, 104, 13-19.
19. Christgen, M., Lehmann, U., MDA-MB-435: The questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol. Ther. 2007, 6, 1355-1357.
20. Harris, R. A., Eichholtz, T. J., Hiles, I. D., Page, M. J., O'Hare, M. J., New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int. J. Cancer 1999, 80, 477-484.
21. Herrero, J., Al-Shahrour, F., Diaz-Uriarte, R., Mateos, A. et al., GEPAS: A web-based resource for microarray gene expression data analysis. Nucleic Acids Res. 2003, 31, 3461-3467.
22. Herrero, J., Diaz-Uriarte, R., Dopazo, J., Gene expression data preprocessing. Bioinformatics 2003, 19, 655-656.
23. Liu, D., Rudland, P. S., Sibson, D. R., Platt-Higgins, A., Barraclough, R., Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res. 2005, 65, 3796-3805.
24. Hartsough, M. T., Steeg, P. S., Nm23/nucleoside diphosphate kinase in human cancers. J. Bioenerg. Biomembr. 2000, 32, 301-308.
25. Olayioye, M. A., Hoffmann, P., Pomorski, T., Armes, J. et al., The phosphoprotein StarD10 is overexpressed in breast cancer and cooperates with ErbB receptors in cellular transformation. Cancer Res. 2004, 64, 3538-3544.
26. Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A. et al., Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994, 263, 526-529.
27. Zhang, D. H., Tai, L. K., Wong, L. L., Sethi, S. K., Koay, E. S., Proteomics of breast cancer: Enhanced expression of cytokeratin 19 in human epidermal growth factor receptor type 2 positive breast tumors. Proteomics 2005, 5, 1797-1805.
28. Grothey, A., Hashizume, R., Sahin, A. A., McCrea, P. D., Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br. J. Cancer 2000, 83, 870-873.
29. Winston, J. S., Asch, H. L., Zhang, P. J., Edge, S. B. et al., Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res. Treat. 2001, 65, 11-21.
30. Shen, D., Chang, H. R., Chen, Z., He, J. et al., Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem. Biophys. vs. Res. Commun. 2005, 326, 218-227.
31. Citri, A., Gan, J., Mosesson, Y., Vereb, G. et al., Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep. 2004, 5, 1165-1170.
32. Zsebik, B., Citri, A., Isola, J., Yarden, Y. et al., Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol. Lett. 2006, 104, 146-155.
33. Neckers, L., Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8, S55-S61.
34. Zhang, D., Tai, L. K., Wang, L. L., Chiu, L. L. et al., Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics 2005, 4, 1686-1696.
35. Brown, N. S., Bicknell, R., Hypoxia and oxidative stress in breast cancer. Oxidative stress: Its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3, 323-327.
36. Oberley, L. W., Buettner, G. R., Role of superoxide dismutase in cancer: A review. Cancer Res. 1979, 39, 1141-1149.
37. Duan, H., Zhang, H. J., Yang, J. Q., Oberley, L. W. et al., MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Antioxid. Redox Signal. 2003, 5, 677-688.
38. Yin, S., Li, X., Meng, Y., Finley, R. L., Jr. et al., Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J. Biol. Chem. 2005, 280, 34985-34996.
39. Leone, A., Flatow, U., VanHoutte, K., Steeg, P. S., Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: Effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene 1993, 8, 2325-2333.
40. Innes, H. E., Liu, D., Barraclough, R., Davies, M. P. et al., Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br. J. Cancer 2006, 94, 1057-1065.
41. Shapland, C., Hsuan, J. J., Tony, N. F., Lawson, D., Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J. Cell Biol. 1993, 121, 1065-1073.
42. Shields, J. M., Rogers-Graham, K., Der, C. J., Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J. Biol. Chem. 2002, 277, 9790-9799.
43. Zhao, H., Jhanwar-Uniyal, M., Datta, P. K., Yemul, S. et al., Expression profile of genes associated with antimetastatic gene: nm23-mediated metastasis inhibition in breast carcinoma cells. Int. J. Cancer 2004, 109, 65-70.
44. Nakopoulou, L. L., Tsitsimelis, D., Lazaris, A. C., Tzonou, A. et al., Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters. Cancer Detect. Prev. 1999, 23, 297-308.
45. Tommasi, S., Fedele, V., Crapolicchio, A., Bellizzi, A. et al., ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion. Int. J. Mol. Med. 2003, 12, 131-134.
46. Thompson, D. A., Weigel, R. J., hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem. Biophys. Res. Commun. 1998, 251, 111-116.
47. Fritzsche, F. R., Dahl, E., Pahl, S., Burkhardt, M. et al., Prognostic relevance of AGR2 expression in breast cancer. Clin. Cancer Res. 2006, 12, 1728-1734.